Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
1-(2-Bromoethyl)-3-chlorobenzene → 1-(3-chlorophenethyl)-3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)imidazolidine-2,4-dione
참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|---|---|---|
| 반응물 | 1-(2-Bromoethyl)-3-chlorobenzene | HCID 140140 | — |
| 반응물 | 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)imidazolidine-2,4-dione | HCID 57422424 | — |
| 생성물 | 1-(3-chlorophenethyl)-3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)imidazolidine-2,4-dione | HCID 57944950 | 27% |
반응 단계
Prepared as in example 10-52 from 3-(1-((3,5-dimethylisoxazol-4-yl)methyl)-1H-pyrazol-4-yl)imidazolidine-2,4-dione (example 10-1) and 3-chlorophenethyl bromide. Yield: 27%. MS M+H calculated 414.13; found 414.2. The title compound was shown to inhibit hT2R08 bitter receptor and had an IC50 of 0.20 μM.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|---|
| 특허 번호 | US07939671B2 |
| 출처 데이터셋 | uspto-grants-2011_05 |
| ORD ID | ord-4aa5067da4cd40b288fb74e9b8e6137b |
| 출처 메모 | uspto-grants-2011_05 |